|
| Meta-analysis of common Chinese medicine injections combined with gemcitabine and cisplatin in the treatment of advanced non-small-cell lung cancer |
| Hits 444 Download times 250 Received:January 23, 2025 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1673-9043.2025.04.08 |
| Key Words
gemcitabine;cisplatin;non-small-cell lung cancer;network Meta-analysis;Chinese medicine injection |
| Author Name | Affiliation | E-mail | | HU Weiwei | The Second Clinical Medical College, Guangzhou University of Traditional Chinese Medicine, Guangzhou 510405, China | | | QIU Sichong | The Second Clinical Medical College, Guangzhou University of Traditional Chinese Medicine, Guangzhou 510405, China | | | TANG Fenglan | The Second Clinical Medical College, Guangzhou University of Traditional Chinese Medicine, Guangzhou 510405, China | | | LI Liuning | Department of Oncology, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510120, China | liliuning97@126.com |
|
| Abstract
|
| [Objective] To evaluate clinical efficacy and safety of six common Chinese medicine injections（CMI） of Aidi Injection，Shenqi Fuzheng Injection，Compound Kushen Injection，Kang’ai Injection，Kanglaite Injection and Xiaoaiping Injection combined with gemcitabine and cisplatin（GP） in the treatment of advanced non-small-cell lung cancer（NSCLC） by network Meta-analysis. [Methods] The databases of CNKI，Wanfang，VIP，China Biomedical Literature Service system，PubMed，Embase and Cochrane Library were searched by computer until December，2022. The Cochrane bias risk tool in the RoB2 Excel tool software was used to assess the bias risk among the selected studies. The Stata 15.0 software was used to make network diagram，league table，surface under the cumulative curve ranking area and funnel plot. [Results] A total of 22 eligible randomized controlled trials were included in this study. The results of network Meta-analysis showed that，with GP as a co-intervention，Aidi Injection and Kanglaite Injection combined with GP could effectively improve the objective response rate（ORR）. Aidi Injection， Shenqi Fuzheng Injection，Compound Kushen Injection，Kang’ai Injection and Kanglaite Injection combined with GP could effectively increase the ratio of CD3+ and CD4+ T cells. Aidi Injection，Shenqi Fuzheng Injection，Kang’ai Injection and Kanglaite Injection combined with GP could effectively increase the ratio of CD4+/CD8+ T cells. Aidi Injection，Shenqi Fuzheng Injection，compound Kushen Injection，Kang’ai Injection，Kanglaite Injection and Xiaoaiping Injection combined with GP could effectively reduce the incidence of leukopenia. Compound Kushen Injection，Kang’ai Injection and Kanglaite Injection combined with GP could effectively reduce the incidence of thrombocytopenia. [Conclusion] CMI combined with GP can effectively improve the clinical efficacy and safety of advanced NSCLC. In terms of improving ORR，reducing the incidence of leukopenia，increasing the ratio of CD4+ T cells and CD4+/CD8+ T cells，Kanglaite Injection is the best. In terms of increasing the ratio of CD3+ T cells，Aidi Injection is the best. In terms of reducing the incidence of thrombocytopenia，Compound Kushen Injection is the best. |
|
